How to beat the market without owning Nvidia shares

Vihari Ross' global fund returned more than 20 per cent in the year to September 30 versus about 10 per cent for the benchmark without owning Nvidia, Meta, Tesla, Apple or Broadcom.

David Rogers

How to beat the market without owning Nvidia shares

November 3, 2025
Vihari Ross' global fund returned more than 20 per cent in the year to September 30 versus about 10 per cent for the benchmark without owning Nvidia, Meta, Tesla, Apple or Broadcom.
Read Transcript

Most investors obsess over Nvidia and the Magnificent Seven these days. Vihari Ross held less than half of them and thrashed the market anyway.

Her Antipodes global fund returned more than 20 per cent in the year to September 30 versus about 10 per cent for the benchmark without owning Nvidia, Meta, Tesla, Apple or Broadcom.

The secret? Looking everywhere else while investors pile into an ever-shrinking group of US tech giants. The former Magellan research boss reckons the game is about to change dramatically.

“The US market is really expensive compared to the rest of the world, but it’s also expensive compared to its own history,” she says. “The US is priced for everything to be completely fine. Perfection, really.”

Ross will be back at the Sohn Hearts & Minds investment conference on November 14.

Her Sohn 2024 stock pick, Airbus, is up about 60 per cent since then and she expects it to keep rallying.

The European aerospace giant benefited from the market broadening beyond US tech, plus strong results from it ramping up plane deliveries and a boost in defence spending.

“It turned out really well and there’s more to go in it. We still own it,” she says.

But her real focus is on what she calls the “gravity of fundamentals” that will eventually pull overvalued stocks back to earth. And right now, she reckons that gravity is about to kick in.

Take Nvidia. The chip designer just added $US1 trillion in market value in three months, fuelled by mammoth spending from tech giants like Amazon, which dropped $US120bn on capital expenditure in a recent quarter.

“One company’s capex is another company’s revenue,” Ross says.

“The nature of capex is it’s supposed to be investment driven. You spend, then you monetise, then you spend more. There could be a capex cycle here.”

Add in rising competition from AMD and the tech giants building their own chips, and Nvidia’s sky-high margins suddenly look vulnerable.

“With all these big technology cycles, the hardware layer ends up becoming commoditised,” she warns. It’s not that these are bad companies. Ross draws a parallel with the tech bubble, when firms like Cisco and Intel were critical to building the internet but simply too expensive.

“They were good companies,” she says. “They just fell because they were expensive.”

Antipodes does own three of the Magnificent Seven tech stocks: Microsoft, Amazon and Alphabet. The latter was bought earlier this year when it traded at 15 times earnings, with investors fearing it would be an AI loser. It’s since rerated to 22 times as that view shifted.

“The market often makes these misjudgements about companies,” Ross says.

But she’s far more excited about what she calls AI “adopters” rather than builders.

“How you can utilise AI, the adopters of AI, is where the more interesting investment ideas lie. They’re the most mispriced because everyone’s already really exuberant about the AI building part.”

Just as Google, Meta and Amazon emerged a decade after the internet bubble to monetise technology, today’s winners might be firms using AI to improve their core businesses.

That search for value has taken Ross well beyond the US.

She’s hunting in the less-glamorous parts of the AI supply chain, owning Japanese firms, Taiwan’s TSMC, and Keysight Technologies, which does systems testing.

“There’s actually much more to an AI supply chain than just the Nvidias of the world,” she says. “Everyone is so hellbent on focusing on this one stock. But there’s a whole industry that sits behind it.”

The fund also holds about 10 per cent in Chinese equities, though Ross took profits after the market rallied hard in February. She sees the Chinese market, trading at 12 times earnings, as the mirror image of America.

“Chinese consumers have $US6.5 trillion sitting in savings. That could be a coiled spring if it starts to be spent when consumer confidence is restored. Everything’s priced for it to be rubbish, but there’s opportunity.”

By contrast, expensive US consumer stocks like Costco, Chipotle and Nike are trading at multiples above 20 times with little growth.

“You can get Alphabet for 22 times. It’s just a really bad deal in that quality consumer side.”

Ross manages risk actively through Antipodes’ long-short fund, which means she can control its net exposure to the market.

The team cut exposure sharply before February’s wobble, then ramped back up in April.

Looking ahead, she sees a familiar pattern emerging.

“You get markets concentrated, you get market peaks, you get overvaluation,” she tells The Australian. “It happens at least once a decade. But it always unwinds in the same way: expensive stocks fall and cheap stocks catch up.”

Her key message for investors? “It’s never been a better time to have differentiated return sources.” Or as Charlie Munger put it: the market’s a weighing machine in the long term, even if it’s a voting machine in the short term.

Ross is keeping her Sohn stock pick under wraps for now, except to say that it’s a smaller, overlooked company outside the US that’s “fallen between the cracks”. It won’t be anywhere near the Magnificent Seven.

Sohn Hearts & Minds returns to the Sydney Opera House this year to feature stock picks from leading investment experts across the globe. All profits go to medical research.

The event has raised $83m over the past decade.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Most investors obsess over Nvidia and the Magnificent Seven these days. Vihari Ross held less than half of them and thrashed the market anyway.

Her Antipodes global fund returned more than 20 per cent in the year to September 30 versus about 10 per cent for the benchmark without owning Nvidia, Meta, Tesla, Apple or Broadcom.

The secret? Looking everywhere else while investors pile into an ever-shrinking group of US tech giants. The former Magellan research boss reckons the game is about to change dramatically.

“The US market is really expensive compared to the rest of the world, but it’s also expensive compared to its own history,” she says. “The US is priced for everything to be completely fine. Perfection, really.”

Ross will be back at the Sohn Hearts & Minds investment conference on November 14.

Her Sohn 2024 stock pick, Airbus, is up about 60 per cent since then and she expects it to keep rallying.

The European aerospace giant benefited from the market broadening beyond US tech, plus strong results from it ramping up plane deliveries and a boost in defence spending.

“It turned out really well and there’s more to go in it. We still own it,” she says.

But her real focus is on what she calls the “gravity of fundamentals” that will eventually pull overvalued stocks back to earth. And right now, she reckons that gravity is about to kick in.

Take Nvidia. The chip designer just added $US1 trillion in market value in three months, fuelled by mammoth spending from tech giants like Amazon, which dropped $US120bn on capital expenditure in a recent quarter.

“One company’s capex is another company’s revenue,” Ross says.

“The nature of capex is it’s supposed to be investment driven. You spend, then you monetise, then you spend more. There could be a capex cycle here.”

Add in rising competition from AMD and the tech giants building their own chips, and Nvidia’s sky-high margins suddenly look vulnerable.

“With all these big technology cycles, the hardware layer ends up becoming commoditised,” she warns. It’s not that these are bad companies. Ross draws a parallel with the tech bubble, when firms like Cisco and Intel were critical to building the internet but simply too expensive.

“They were good companies,” she says. “They just fell because they were expensive.”

Antipodes does own three of the Magnificent Seven tech stocks: Microsoft, Amazon and Alphabet. The latter was bought earlier this year when it traded at 15 times earnings, with investors fearing it would be an AI loser. It’s since rerated to 22 times as that view shifted.

“The market often makes these misjudgements about companies,” Ross says.

But she’s far more excited about what she calls AI “adopters” rather than builders.

“How you can utilise AI, the adopters of AI, is where the more interesting investment ideas lie. They’re the most mispriced because everyone’s already really exuberant about the AI building part.”

Just as Google, Meta and Amazon emerged a decade after the internet bubble to monetise technology, today’s winners might be firms using AI to improve their core businesses.

That search for value has taken Ross well beyond the US.

She’s hunting in the less-glamorous parts of the AI supply chain, owning Japanese firms, Taiwan’s TSMC, and Keysight Technologies, which does systems testing.

“There’s actually much more to an AI supply chain than just the Nvidias of the world,” she says. “Everyone is so hellbent on focusing on this one stock. But there’s a whole industry that sits behind it.”

The fund also holds about 10 per cent in Chinese equities, though Ross took profits after the market rallied hard in February. She sees the Chinese market, trading at 12 times earnings, as the mirror image of America.

“Chinese consumers have $US6.5 trillion sitting in savings. That could be a coiled spring if it starts to be spent when consumer confidence is restored. Everything’s priced for it to be rubbish, but there’s opportunity.”

By contrast, expensive US consumer stocks like Costco, Chipotle and Nike are trading at multiples above 20 times with little growth.

“You can get Alphabet for 22 times. It’s just a really bad deal in that quality consumer side.”

Ross manages risk actively through Antipodes’ long-short fund, which means she can control its net exposure to the market.

The team cut exposure sharply before February’s wobble, then ramped back up in April.

Looking ahead, she sees a familiar pattern emerging.

“You get markets concentrated, you get market peaks, you get overvaluation,” she tells The Australian. “It happens at least once a decade. But it always unwinds in the same way: expensive stocks fall and cheap stocks catch up.”

Her key message for investors? “It’s never been a better time to have differentiated return sources.” Or as Charlie Munger put it: the market’s a weighing machine in the long term, even if it’s a voting machine in the short term.

Ross is keeping her Sohn stock pick under wraps for now, except to say that it’s a smaller, overlooked company outside the US that’s “fallen between the cracks”. It won’t be anywhere near the Magnificent Seven.

Sohn Hearts & Minds returns to the Sydney Opera House this year to feature stock picks from leading investment experts across the globe. All profits go to medical research.

The event has raised $83m over the past decade.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on Nov 03, 2025. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Azora Capital founder Ravi Chopra. Picture: Renee NowytargerAzora Capital founder Ravi Chopra. Picture: Renee NowytargerAzora Capital founder Ravi Chopra. Picture: Renee NowytargerAzora Capital founder Ravi Chopra. Picture: Renee Nowytarger
November 17, 2023

Webster Financial ‘Avoided The Mistakes Of US Bank Failures’

The US financial sector is not without its problems but Ravi Chopra backs Webster Financial Corporation as his stock pick for the 2023 Sohn Hearts & Minds Investment Leaders Conference.

Read More
November 17, 2023

Why Stock Picker Cathie Wood Of ARK Can’t Stand Google

The world’s highest-profile tech investor, Cathie Wood, might be bruised but she is certainly bullish. Nor is she holding back.

Read More
Munro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee NowytargerMunro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee NowytargerMunro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee NowytargerMunro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee Nowytarger
November 17, 2023

Wise Share Price Could Rise 50pc By 2025, Says Munro Partners

Global growth fund manager Munro has about $4.3bn in funds under management across four global funds, and usually invests in companies that are poised to win from massive structural change.

Read More
November 16, 2023

Hedge Fund Veteran Talks Lowest Moment In Toscafund’s 23-Year Run

Most hedge fund managers brag about their wins and shy away from their losses – Martin Hughes is not most hedge fund managers.

Read More
November 16, 2023

The ‘Armageddon Scenario’ Worrying The Future Fund CIO

Mr Samild shared his thoughts on the bond market – which underpins the returns of other assets – ahead of his appearance at Friday’s Sohn Hearts & Minds charity conference at the Sydney Opera House.

Read More
Daniel MacArthur with Melbourne scientist and assistant professor Misty Jenkins. Both will be speaking at the Sohn Hearts & Minds conference in Sydney.Daniel MacArthur with Melbourne scientist and assistant professor Misty Jenkins. Both will be speaking at the Sohn Hearts & Minds conference in Sydney.Daniel MacArthur with Melbourne scientist and assistant professor Misty Jenkins. Both will be speaking at the Sohn Hearts & Minds conference in Sydney.Daniel MacArthur with Melbourne scientist and assistant professor Misty Jenkins. Both will be speaking at the Sohn Hearts & Minds conference in Sydney.
November 15, 2023

Advancing Medicine Is In Daniel MacArthur’s DNA

When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.

Read More
November 15, 2023

Ashish Swarup - Invest In Snacks, Let's Get That Bread | Aikya Investment Management

Ashish Swarup, Portfolio Manager and Investment Analyst of Aikya Investment Management joins Bryce and Ren to discuss emerging markets, and two stock deep dives.

Read More
November 15, 2023

Daniel Loeb’s Wall St Hedge Fund Third Point Raises Bets On Corporate Credit Crunch

An “obsession” around balance sheet strength and debt is creating a new wave of investment bets for the influential Wall Street hedge fund run by Daniel Loeb.

Read More
November 13, 2023

Bond Bullish On Commodity Stocks, Uranium

Mining stocks are poised to rise amid tight supply for key commodities such as copper, nickel and uranium, says Terra Capital founder Jeremy Bond.

Read More
November 13, 2023

This Hedge Fund Manager Is Making A 100-Year Bet On Luxury

European leisure and luxury – a designer handbag, a last-minute flight to Monte Carlo, a stay in a five-star hotel – is where many choose to spend their hard-earned cash. For Sharif el Khazen, it’s where he makes it.

Read More
November 12, 2023

How Munro Will Pick Its Next Stock Winner

Munro partner and portfolio manager Kieran Moore must select a single company to pitch to an audience of industry heavyweights at the prestigious Sohn Hearts & Minds conference in Sydney.

Read More
November 12, 2023

The Australian At The Centre Of Dalio’s Bridgewater – Who Loves It

The culture at Ray Dalio’s massive hedge fund has been a source of intrigue, and with a new book, controversy. Atul Lele says it’s made him a better investor.

Read More
November 10, 2023

Meet The Goldman Sachs Legend Shaking Up Venture Capital

Sheila Patel says it was time for the venture capital sector to “grow up” and higher rates will help do that job. VC firms need to think differently about how they invest.

Read More
November 8, 2023

Tom Naughton - There's Money In Mi Goreng | Prusik Investment

Tom Naughton is Managing Partner and CIO at Prusik Investment. In this episode, he chats to Equity Mates ahead of his appearance at the 2023 Sohn Hearts and Minds Conference.

Read More
November 6, 2023

Why Chris Kourtis just bought CSL and ResMed

A true contrarian investor, Chris Kourtis can find himself sounding a lot like a bull when in the company of bears, and there’s a lot to be bearish about at the moment.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.